New ROS Lumacaftor | VX-809 | CAS#936727-05-8

EOS Med Chem, now have a GMP plant in Taizhou city. Regular produce some Intermediates and custom synthesis.

The plant have approved by TEVA, HIKMA, CIPLA, GLENMARK, MAYLAN and some others.

Now my plant have 40 workers, 15 Tech person, 4 high Tech person.

And my source team have 4 source man, each one have more than 10 years in China market, they are clear COST and DELIVERY time.

Each day, we have new chemicals or price from my lab or plant.

New ROS Lumacaftor | VX-809 | CAS#936727-05-8

Lumacaftor | VX-809 | CAS#936727-05-8, now API we have 1000g in stock.

Intermediates, we could supply: 

89446-17-1, this is my sole route, use this Intermediates, only 2 step could finish the API. Assay more than 99%, Loss on drying, less than 0.5%.

220210-56-0, this is step raw material.  Assay more than 99%, Loss on drying, less than 0.5%.

862574-88-7, we have big advantage of this chemical, 12kg in stock.  Assay more than 99%, Loss on drying, less than 0.5%.

1378388-16-9, This is new step of chemical.

HPLC, NMR, MS, pls kindly check below.

Welcome to ask me.

2016 Shanghai CPHI, W5C47, Welcome!

EOS Med Chem, Medchem is Big

執大象，天下往，往而無害，安平泰

網址: www.eosmedchem.com 

郵箱: gutian@eosmedchem.com; eosmedchem@gmail.com 

辦公室: 0086-531-69905422-806(直通)

攜帶番號 & WhatsApp: +8618653174435

Skype: willgutian

2016 New Oncology List

2016 New Oncology List

API
1	AZD3759	1626387-80-1	＞99.5%
2	Rucaparib	283173-50-2	＞99%
3	AG-014699	459868-92-9	＞99%
4	ABT-199	1257044-40-8	＞99%
5	WZ4002	1213269-23-8	＞99%
6	WZ8040	1214265-57-2	＞99%
7	WZ3146	1214265-56-1	＞99%

GMP-AP26113 (CAS 1197958-12-5)

GMP-AP26113 (CAS 1197958-12-5)

AP26113
Int 1	(2-Aminophenyl)dimethylphosphine oxide	1197953-47-1	＞98%
Int 2	2,5-dichloro-N-(2-(diMethylphosphoryl)phenyl)pyriMidin-4-aMine	1197953-49-3	＞98%
Int 3	1-(4-amino-3-methoxyphenyl)-N,N-dimethylpiperidin-4-amine	1089279-91-3	＞98%

GMP• Ribociclib (CAS 1211441-98-3)

GMP• Ribociclib (CAS 1211441-98-3)

ribociclibAn orally available cyclin-dependent kinase (CDK) inhibitor targeting cyclin D1/CDK4 and cyclin D3/CDK6 cell cycle pathway, with potential antineoplastic activity. Ribociclib specifically inhibits CDK4 and 6, thereby inhibiting retinoblastoma (Rb) protein phosphorylation.

Ribociclib （LEE011）
Int 1	7H-Pyrrolo[2,3-d]pyriMidine-6-carboxaMide, 2-chloro-7-cyclopentyl-N,N-diMethyl-	1211443-61-6	＞98%
Int 2	tert-Butyl 4-(6-(7-cyclopentyl-6-(dimethylcarbamoyl)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)pyridin-3-yl)piperazine-1-carboxylate	1374639-78-7	＞98%

Med-chemicals, I am big

Web: www.eosmedchem.com

Email: info@eosmedchem.com; eosmedchem@gmail.com

Office line: 0086-531-69905422

GMP-Abemaciclib (LY2835219) CAS 1231929-97-7

GMP-Abemaciclib (LY2835219) CAS 1231929-97-7

abemaciclibAn orally available cyclin-dependent kinase (CDK) inhibitor that targets the CDK4 (cyclin D1) and CDK6 (cyclin D3) cell cycle pathway, with potential antineoplastic activity. Abemaciclib specifically inhibits CDK4 and 6, thereby inhibiting retinoblastoma (Rb) protein phosphorylation in early G1.

Abemaciclib (LY2835219)
	N-(4-bromo-2,6-difluoro-phenyl)-N’-isopropyl-acetamidine	1231930-29-2	＞98%
Int 1	1H-BenziMidazole,6-(2-chloro-5-fluoro-4-pyriMidinyl)-4-fluoro-2-Methyl-1-(1-Methylethyl)	1231930-42-9	＞98%
Int 2	5-[(4-ethylpiperazin-1-yl)methyl]pyridin-2-amine	1180132-17-5	＞98%
Int 3	4-fluoro-1-isopropyl-2-methyl-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-benzo[d]imidazole	1231930-37-2	＞98%
Int 4	6-Bromo-4-fluoro-1-isopropyl-2-methyl-1H-benzo[d]imidazole	1231930-33-8	＞98%

GMP – Rociletinib (CO-1686) 1374640-70-6

GMP – Rociletinib (CO-1686) 1374640-70-6

Rociletinib (CO-1686) is a novel, oral, targeted covalent (irreversible) inhibitor of the cancer-causing mutant forms of epidermal growth factor receptor (EGFR) currently being studied for the treatment of non-small cell lung cancer (NSCLC). Rociletinib was designed to selectively target both the initial activating EGFR mutations and the dominant acquired T790M resistance mutation, while sparing wild-type, or normal EGFR at anticipated therapeutic doses, with an improved toxicity profile.

Rociletinib (CO-1686)
	Rociletinib Hydrobromide	N/A	＞98%
Int 1	N-[3-[[2-Chloro-5-(trifluoromethyl)-4-pyrimidinyl]amino]phenyl]carbamic acid 1,1-dimethylethyl ester	1374507-23-9	＞98%
Int 2	(3-Aminophenyl)carbamic acid tert-butyl ester	68621-88-5	＞98%
Int 3	4-(4-Acetyl-1-piperazinyl)-2-(methyloxy)aniline	1021426-42-5	＞98%
Int 4	1-Acetyl-4-[3-(methyloxy)-4-nitrophenyl]piperazine	1116229-11-8	＞98%

New Oncology: HM-61713 CAS 1802181-20-9 (BI-1482694) Intermediates all from GMP plant is coming

New Oncology: HM-61713 CAS 1802181-20-9 (BI-1482694) Intermediates all from GMP plant is coming

Boehringer Ingelheim

As 2016, EOS Med new project, now each batch is about 10kg, we have 3kg in stock. Welcome to ask.

Int 1	N/A	N/A	＞98%
Int 2	N/A	N/A	＞98%
Int 3	N/A	1353553-07-7	＞98%
Int 4	4-(4-Methylpiperazino)aniline	16153-81-4	＞98%
Int 5	2,4-Dichlorothieno[3,2-d]pyrimidine	16234-14-3	＞98%

Osimertinib AZD9291, 1421373-65-0 , 99.5%

Osimertinib AZD9291, 1421373-65-0 , 99.5%

TAGRISSO™ (AZD9291) approved by the US FDA for patients with EGFR T790M mutation-positive metastatic non-small cell lung cancer.

EOS Med Chem, finish it in 2015, Nov. EE is 99.5%.

Osimertinib AZD9291
Int 1	N-[2-[[2-(Dimethylamino)ethyl]methylamino]-4-methoxy-5-[[4-(1-methyl-1H-indol-3-yl)-2-pyrimidinyl]amino]phenyl]-2-propenamide	1421373-65-0	＞99.5
Int 2	N1-[2-(Dimethylamino)ethyl]-5-methoxy-N1-methyl-N4-[4-(1-methyl-1H-indol-3-yl)-2-pyrimidinyl]-2-nitro-1,4-benzenediamine	1421372-67-9	＞98%
Int 3	N-(4-Fluoro-2-methoxy-5-nitrophenyl)-4-(1-methyl-1H-indol-3-yl)-2-pyrimidinamine	1421372-94-2	＞98%
Int 4	3-(2-Chloro-4-pyrimidinyl)-1-methyl-1H-indole	1032452-86-0	＞98%